Cryo-Cell International Granted Compliance Period by NYSE American
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy CCEL?
Source: seekingalpha
- Compliance Plan Approved: Cryo-Cell International announced that its compliance plan has been approved by NYSE American, allowing it until September 9, 2027, to regain compliance with listing standards, demonstrating the company's proactive strategy in addressing financial challenges.
- Financial Condition Disclosure: The company disclosed in March that it failed to comply with Section 1003(a) of the NYSE American Company Guide due to a stockholders' deficit as of November 30, 2025, and net losses in two of its three most recent fiscal years, reflecting its fragile financial health.
- Continued Listing Assurance: During the compliance period, Cryo-Cell's shares will continue to be traded on NYSE American, indicating that the company can maintain market liquidity and investor confidence while working to improve its financial situation.
- Potential Risk Warning: If Cryo-Cell fails to regain compliance by the deadline or does not make progress under the plan, NYSE American may initiate delisting proceedings, posing a potential threat to the company's long-term development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CCEL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CCEL
About CCEL
Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 240,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cryo-Cell International Granted Compliance Period by NYSE American
- Compliance Plan Approved: Cryo-Cell International announced that its compliance plan has been approved by NYSE American, allowing it until September 9, 2027, to regain compliance with listing standards, demonstrating the company's proactive strategy in addressing financial challenges.
- Financial Condition Disclosure: The company disclosed in March that it failed to comply with Section 1003(a) of the NYSE American Company Guide due to a stockholders' deficit as of November 30, 2025, and net losses in two of its three most recent fiscal years, reflecting its fragile financial health.
- Continued Listing Assurance: During the compliance period, Cryo-Cell's shares will continue to be traded on NYSE American, indicating that the company can maintain market liquidity and investor confidence while working to improve its financial situation.
- Potential Risk Warning: If Cryo-Cell fails to regain compliance by the deadline or does not make progress under the plan, NYSE American may initiate delisting proceedings, posing a potential threat to the company's long-term development.
See More
CRYO-CELL International Reports Q1 Earnings
- Earnings Highlights: CRYO-CELL International reported a GAAP EPS of $0.01 for Q1, indicating basic profitability despite a decline compared to the previous year, which may affect investor sentiment.
- Revenue Decline: The company generated $7.68 million in revenue for the first quarter, reflecting a 3.6% year-over-year decrease, suggesting revenue growth challenges in a competitive market that could impact future investor confidence.
- Compliance Notice: CRYO-CELL International received a notice from NYSE American regarding non-compliance with listing requirements, potentially leading to further compliance challenges that could affect its market reputation and shareholder trust.
- Rating Analysis: According to Seeking Alpha's Quant Rating, CRYO-CELL International's market performance is under scrutiny, prompting investors to closely monitor its future financial performance and compliance progress to assess investment risks.
See More
Cryo-Cell International Reports Q1 Financial Results
- Revenue Decline: Cryo-Cell International reported Q1 2026 revenues of $7.68 million, a 3.6% decrease from $7.97 million in Q1 2025, primarily due to a drop in processing and storage fee revenues, indicating signs of weakened market demand.
- Net Income Drop: The company reported a net income of approximately $47,000, or $0.01 per basic and diluted share, significantly down from $283,000 and $0.03 per share in the same period of 2025, reflecting a substantial decline in profitability.
- Market Positioning: As the world's first private cord blood bank, Cryo-Cell currently stores over 250,000 cord blood and tissue specimens, and despite revenue challenges, the company remains committed to providing high-quality biostorage solutions to maintain its market leadership.
- Future Outlook: The company faces risks and uncertainties in expanding its global business and product diversification, particularly in its plans for biopharmaceutical manufacturing and operating clinics, which may impact future profitability and competitive positioning.
See More
Cryo-Cell International Receives NYSE Compliance Notice
- Compliance Warning: Cryo-Cell International has received a notice from NYSE American indicating non-compliance due to stockholder deficit as of November 30, 2025, and net losses in two of the last three fiscal years, which could jeopardize its listing status.
- Financial Condition Analysis: The notice highlights financial challenges faced by Cryo-Cell in fiscal years 2023, 2024, and 2025, particularly the existence of stockholder deficits, indicating pressure on the company's profitability and financial health.
- Compliance Plan Submission: Cryo-Cell plans to submit a compliance plan to the exchange, and if accepted, the company could have up to 18 months to regain compliance, providing a buffer period to improve its financial situation.
- Trading Impact: Despite the warning, Cryo-Cell emphasizes that the notice has no immediate effect on the listing or trading of its common stock, indicating that the company is actively managing its market position.
See More
Cryo-Cell International Reports Fiscal 2025 Results
- Revenue Decline: Cryo-Cell International reported consolidated revenues of $31.6 million for fiscal 2025, down from $32.0 million in fiscal 2024, primarily due to a decrease in public banking revenue, indicating signs of weakened market demand that could impact future cash flows.
- Increased Net Loss: The company reported a net loss of $2.4 million for fiscal 2025, translating to a loss of $0.30 per share, compared to a net income of $402,000 in fiscal 2024, highlighting increased operational pressures that necessitate measures to improve financial health.
- Impairment Charge Impact: An impairment charge of $4.4 million was recognized in Q4 2025 due to changes in sales trends and estimated recoverability of inventory, reflecting challenges in inventory management and market adaptability that may affect investor confidence.
- Strong Market Position: Despite financial challenges, Cryo-Cell remains the world's first private cord blood bank, having served over 500,000 parents and partnering with Duke University for its public banking program, thereby continuing to solidify its leadership position in the industry.
See More
Cryo-Cell International Reports Fiscal 2025 Results
- Revenue Decline: Cryo-Cell International reported consolidated revenues of $31.6 million for fiscal 2025, a decrease from $32.0 million in fiscal 2024, primarily due to a drop in processing and storage fee income, indicating increased competitive pressure in the market.
- Widening Net Loss: The company reported a net loss of $2.4 million for fiscal 2025, translating to a loss of $0.30 per share, compared to a net income of $402,000 in fiscal 2024, reflecting a significant deterioration in financial health.
- Impairment Loss Impact: An impairment charge of $4.4 million was recognized in Q4 2025 due to changes in sales trends and inventory recoverability assessments, leading to a substantial reduction in public inventory value and exacerbating financial strain.
- Market Position Challenges: As the world's first private cord blood bank, Cryo-Cell faces competitive pressure from public cord blood banks, necessitating a focus on strengthening core business and product diversification to maintain market share.
See More
Cryo-Cell International Granted Compliance Period by NYSE American
- Compliance Plan Approved: Cryo-Cell International announced that its compliance plan has been approved by NYSE American, allowing it until September 9, 2027, to regain compliance with listing standards, demonstrating the company's proactive strategy in addressing financial challenges.
- Financial Condition Disclosure: The company disclosed in March that it failed to comply with Section 1003(a) of the NYSE American Company Guide due to a stockholders' deficit as of November 30, 2025, and net losses in two of its three most recent fiscal years, reflecting its fragile financial health.
- Continued Listing Assurance: During the compliance period, Cryo-Cell's shares will continue to be traded on NYSE American, indicating that the company can maintain market liquidity and investor confidence while working to improve its financial situation.
- Potential Risk Warning: If Cryo-Cell fails to regain compliance by the deadline or does not make progress under the plan, NYSE American may initiate delisting proceedings, posing a potential threat to the company's long-term development.
See More
CRYO-CELL International Reports Q1 Earnings
- Earnings Highlights: CRYO-CELL International reported a GAAP EPS of $0.01 for Q1, indicating basic profitability despite a decline compared to the previous year, which may affect investor sentiment.
- Revenue Decline: The company generated $7.68 million in revenue for the first quarter, reflecting a 3.6% year-over-year decrease, suggesting revenue growth challenges in a competitive market that could impact future investor confidence.
- Compliance Notice: CRYO-CELL International received a notice from NYSE American regarding non-compliance with listing requirements, potentially leading to further compliance challenges that could affect its market reputation and shareholder trust.
- Rating Analysis: According to Seeking Alpha's Quant Rating, CRYO-CELL International's market performance is under scrutiny, prompting investors to closely monitor its future financial performance and compliance progress to assess investment risks.
See More
Cryo-Cell International Reports Q1 Financial Results
- Revenue Decline: Cryo-Cell International reported Q1 2026 revenues of $7.68 million, a 3.6% decrease from $7.97 million in Q1 2025, primarily due to a drop in processing and storage fee revenues, indicating signs of weakened market demand.
- Net Income Drop: The company reported a net income of approximately $47,000, or $0.01 per basic and diluted share, significantly down from $283,000 and $0.03 per share in the same period of 2025, reflecting a substantial decline in profitability.
- Market Positioning: As the world's first private cord blood bank, Cryo-Cell currently stores over 250,000 cord blood and tissue specimens, and despite revenue challenges, the company remains committed to providing high-quality biostorage solutions to maintain its market leadership.
- Future Outlook: The company faces risks and uncertainties in expanding its global business and product diversification, particularly in its plans for biopharmaceutical manufacturing and operating clinics, which may impact future profitability and competitive positioning.
See More
Cryo-Cell International Receives NYSE Compliance Notice
- Compliance Warning: Cryo-Cell International has received a notice from NYSE American indicating non-compliance due to stockholder deficit as of November 30, 2025, and net losses in two of the last three fiscal years, which could jeopardize its listing status.
- Financial Condition Analysis: The notice highlights financial challenges faced by Cryo-Cell in fiscal years 2023, 2024, and 2025, particularly the existence of stockholder deficits, indicating pressure on the company's profitability and financial health.
- Compliance Plan Submission: Cryo-Cell plans to submit a compliance plan to the exchange, and if accepted, the company could have up to 18 months to regain compliance, providing a buffer period to improve its financial situation.
- Trading Impact: Despite the warning, Cryo-Cell emphasizes that the notice has no immediate effect on the listing or trading of its common stock, indicating that the company is actively managing its market position.
See More
Cryo-Cell International Reports Fiscal 2025 Results
- Revenue Decline: Cryo-Cell International reported consolidated revenues of $31.6 million for fiscal 2025, down from $32.0 million in fiscal 2024, primarily due to a decrease in public banking revenue, indicating signs of weakened market demand that could impact future cash flows.
- Increased Net Loss: The company reported a net loss of $2.4 million for fiscal 2025, translating to a loss of $0.30 per share, compared to a net income of $402,000 in fiscal 2024, highlighting increased operational pressures that necessitate measures to improve financial health.
- Impairment Charge Impact: An impairment charge of $4.4 million was recognized in Q4 2025 due to changes in sales trends and estimated recoverability of inventory, reflecting challenges in inventory management and market adaptability that may affect investor confidence.
- Strong Market Position: Despite financial challenges, Cryo-Cell remains the world's first private cord blood bank, having served over 500,000 parents and partnering with Duke University for its public banking program, thereby continuing to solidify its leadership position in the industry.
See More
Cryo-Cell International Reports Fiscal 2025 Results
- Revenue Decline: Cryo-Cell International reported consolidated revenues of $31.6 million for fiscal 2025, a decrease from $32.0 million in fiscal 2024, primarily due to a drop in processing and storage fee income, indicating increased competitive pressure in the market.
- Widening Net Loss: The company reported a net loss of $2.4 million for fiscal 2025, translating to a loss of $0.30 per share, compared to a net income of $402,000 in fiscal 2024, reflecting a significant deterioration in financial health.
- Impairment Loss Impact: An impairment charge of $4.4 million was recognized in Q4 2025 due to changes in sales trends and inventory recoverability assessments, leading to a substantial reduction in public inventory value and exacerbating financial strain.
- Market Position Challenges: As the world's first private cord blood bank, Cryo-Cell faces competitive pressure from public cord blood banks, necessitating a focus on strengthening core business and product diversification to maintain market share.
See More
